share_log

3-Year VenoValve First-In-Human Data Presented At 49th Annual VEITH Symposium On Vascular And Endovascular Issues

Benzinga Real-time News ·  Nov 17, 2022 12:04
  • First-in-Human VenoValve recipients continue to benefit from VenoValve at average of 3 years post-surgery
  • No venous ulcer recurrences or CVI relapses
  • Stability in improvements for all study endpoints including reflux, disease severity (rVCSS), and pain (VAS)

IRVINE, CA / ACCESSWIRE / November 17, 2022 /enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Principal Investigator Dr. Jorge Hernando Ulloa presented positive long-term, three-year observational data from a cohort of patients that participated in the previously concluded VenoValve first-in-human clinical trial.

The data...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment